Upgrade to SI Premium - Free Trial

Clearmind Medicine (CMND)

1.16 -0.54 (31.76%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/15/25 *Est.)

Latest Headlines

Clearmind Medicine to acquire 51% of EV wireless charging firm September 4, 2026 7:32 AM - StreetInsider Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis September 4, 2026 7:32 AM - StreetInsider Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder September 1, 2026 7:37 AM - StreetInsider Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled September 1, 2026 7:37 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Aug 24 August 24, 2026 4:01 PM - SEC Filing SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD August 24, 2026 8:51 AM - StreetInsider SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation August 24, 2026 8:51 AM - StreetInsider Clearmind files U.S. patent for MDMA-PEA combination to treat PTSD August 24, 2026 8:05 AM - StreetInsider Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation August 24, 2026 8:03 AM - StreetInsider Clearmind gets DSMB approval to test CMND-100 in AUD patients August 13, 2026 7:36 AM - StreetInsider Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint August 13, 2026 7:36 AM - StreetInsider Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: Iroquois Capital Management, LLC August 12, 2026 10:46 AM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Aug 11 August 11, 2026 4:01 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Aug 06 August 6, 2026 4:00 PM - SEC Filing Clearmind gets clearance to advance AUD drug trial to patient cohorts August 6, 2026 8:00 AM - StreetInsider Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study August 6, 2026 8:00 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Aug 03 August 3, 2026 8:12 AM - SEC Filing Clearmind Medicine eyes 51% stake in EV wireless charging firm August 3, 2026 8:02 AM - StreetInsider Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company August 3, 2026 8:02 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 30 July 30, 2026 4:01 PM - SEC Filing Clearmind reports no serious adverse events in CMND-100 dose trial July 30, 2026 8:30 AM - StreetInsider Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial July 30, 2026 8:30 AM - StreetInsider Clearmind completes Part A of Phase I/II trial for alcohol disorder drug July 28, 2026 7:47 AM - StreetInsider Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial July 28, 2026 7:47 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 20 July 20, 2026 4:00 PM - SEC Filing Clearmind Medicine files Hong Kong patent for PTSD compounds July 20, 2026 7:55 AM - StreetInsider Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market July 20, 2026 7:55 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 17 July 17, 2026 4:02 PM - SEC Filing FDA issues psychedelic therapy guidance as Clearmind notes federal push July 17, 2026 7:32 AM - StreetInsider Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction July 17, 2026 7:32 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 16 July 16, 2026 1:39 PM - SEC Filing Clearmind reports improved nasal retention for its MEAI drug formulation July 16, 2026 9:30 AM - StreetInsider Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI July 16, 2026 9:30 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 13 July 13, 2026 4:01 PM - SEC Filing Clearmind reports early safety data from CMND-100 alcohol disorder trial July 13, 2026 8:17 AM - StreetInsider Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial July 13, 2026 8:17 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 10 July 10, 2026 4:00 PM - SEC Filing Clearmind Medicine submits response to HHS addiction treatment RFI July 10, 2026 8:32 AM - StreetInsider Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative July 10, 2026 8:32 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 07 July 7, 2026 4:01 PM - SEC Filing Clearmind reports MEAI intranasal formulation feasibility study success July 7, 2026 7:43 AM - StreetInsider Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI July 7, 2026 7:42 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jun 29 June 29, 2026 8:12 AM - SEC Filing Clearmind Medicine receives new U.S. patent for binge behavior treatments June 29, 2026 7:55 AM - StreetInsider Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength June 29, 2026 7:55 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jun 22 June 22, 2026 8:08 AM - SEC Filing Clearmind completes Part A of FDA-regulated AUD drug trial June 22, 2026 8:07 AM - StreetInsider Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial June 22, 2026 8:07 AM - StreetInsider Form EFFECT Clearmind Medicine Inc. June 22, 2026 6:03 AM - SEC Filing Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP June 18, 2026 5:06 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Jun 18 June 18, 2026 8:11 AM - SEC Filing Clearmind Medicine receives U.S. patent for binge behavior compound June 18, 2026 7:55 AM - StreetInsider Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators June 18, 2026 7:55 AM - StreetInsider Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP June 17, 2026 4:43 PM - SEC Filing Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP June 16, 2026 9:19 AM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Jun 16 June 16, 2026 7:35 AM - SEC Filing Clearmind Medicine completes Part A dosing in Phase I/II alcohol disorder trial June 16, 2026 7:32 AM - StreetInsider Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial June 16, 2026 7:32 AM - Globe NewsWire Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial June 16, 2026 7:32 AM - StreetInsider Form POS AM Clearmind Medicine Inc. June 15, 2026 5:10 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Apr 30 June 15, 2026 4:02 PM - SEC Filing Form 4 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP June 12, 2026 4:29 PM - SEC Filing Form 3 Clearmind Medicine Inc. For: Jun 10 Filed by: HRT FINANCIAL LP June 12, 2026 4:19 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Jun 12 June 12, 2026 4:01 PM - SEC Filing Full Article List